Skip to search formSkip to main contentSkip to account menu

EGFR Inhibitor HM61713

Known as: HM61713 
An orally available small molecule, mutant-selective inhibitor of epidermal growth factor receptor (EGFR) with potential antineoplastic activity… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
EGFR-activating mutations are observed in approximately 15% to 20% of patients with non-small cell lung cancer. Tyrosine kinase… 
Review
2016
Review
2016
The tyrosine kinase inhibitors (TKI) against epidermal growth factor receptor (EGFR) are widely used in patients with non-small… 
Highly Cited
2016
2016
2016
9055Background: T790M mediates acquired resistance to 1st/2nd generation EGFR-TKIs. BI 1482694 is a 3rd generation TKI active… 
Highly Cited
2015
Highly Cited
2015
8084 Background: HM61713 is an orally available EGFR mutation-specific inhibitor with sparing EGFR WT tumors that previously… 
Highly Cited
2014
Highly Cited
2014
8011 Background: HM61713 is a novel, oral, selective inhibitor for EGFR mutations including both activating mutations and T790M… 
2014
2014
Introduction: Activating mutations of EGFR are well known as oncogenic driver mutations in lung adenocarcinoma. Currently, EGFR…